China
Africa
Explore chapters and articles related to this topic
Endocrine tumors in pregnancy
Published in Nadia Barghouthi, Jessica Perini, Endocrine Diseases in Pregnancy and the Postpartum Period, 2021
Immediately following evacuation, Rho (D) immunoglobulin should be administered for Rh-negative patients.1,8,9 This is not necessary if hysterectomy is performed.
Prehospital Transfusion of Low-Titer O + Whole Blood for Severe Maternal Hemorrhage: A Case Report
Published in Prehospital Emergency Care, 2020
Ryan Newberry, C. J. Winckler, Ryan Luellwitz, Leslie Greebon, Elly Xenakis, William Bullock, Michael Stringfellow, Julian Mapp
RhD alloimmunization has been successfully prevented with the administration of Rho(D) immune globulin, also known as RhoGAM (RhIg). A standard pre-natal or post-natal dose of RhIg consists of a single 300 microgram (ug) vial and is administered intravenously or intramuscularly, depending on the manufacturer. Each 300 ug vial effectively prevents alloimmunization after exposure to 15 mL of Rh + PRBCs or 30 mLs of Rh + whole blood. Typically, Rh- women receive anti-D immunoglobulin within 72 hours after suspected fetal-maternal hemorrhage, miscarriage, ectopic pregnancy and delivery to prevent the formation of antibodies against RhD (21–23). Maternal RhD alloimmunization can have significant implications in subsequent pregnancies, including hemolytic disease of the fetus (14). With the risk of maternal RhD alloimmunization, it is prudent to evaluate if women of childbearing age should receive LTO + WB.
Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis
Published in Journal of Medical Economics, 2020
Derek Weycker, Ahuva Hanau, Mark Hatfield, Hongsheng Wu, Anjali Sharma, Mark E. Bensink, David Chandler, Aaron Grossman, Michael Tarantino
The decision to treat depends on a number of cofactors, including age, platelet count, and conditions/drugs predisposing to bleeding1,7. Given the nature of pediatric ITP, observation alone is recommended as initial management for children who do not experience severe bleeding, followed by treatment as necessary1,7. For adults, treatment may be recommended immediately following diagnosis, depending on platelet count and other patient cofactors, and consists of raising platelet levels to a safe range1,8,11,12. Standard frontline therapy for children and adults with ITP includes corticosteroids; alternative therapies include immunoglobulin therapy, Rho(D) immune globulin (RhD-Ig), and/or platelet transfusion1,7,8. Second-line therapies include thrombopoietin receptor agonists (eltrombopag and romiplostim), rituximab, and splenectomy1,7,8,13,14.